<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198494</url>
  </required_header>
  <id_info>
    <org_study_id>17-00698</org_study_id>
    <nct_id>NCT03198494</nct_id>
  </id_info>
  <brief_title>Acoustic Stimulation for Seizure Suppression</brief_title>
  <official_title>Low Frequency Acoustic Stimulation During Sleep for Seizure Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the feasibility and physiological effect of&#xD;
      low-frequency (1 Hz) acoustic stimulation delivered during nocturnal NREM sleep in epilepsy&#xD;
      patients. The long-term goal is to develop this protocol for daily, long-term use in a home&#xD;
      setting, for nocturnal seizure and IED suppression&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To test the feasibility of wearing an earphone system delivering acoustic stimulation&#xD;
           during a night of sleep in adult epilepsy patients monitored in an inpatient unit.&#xD;
&#xD;
        2. To determine the acute physiological effects of low-frequency acoustic stimulation on&#xD;
           interictal epileptiform discharge (IED) frequency during NREM sleep in adult patients&#xD;
           with epilepsy in an ambulatory setting.&#xD;
&#xD;
        3. To determine the feasibility of applying low-frequency acoustic stimulation in a&#xD;
           long-term home setting in adult epilepsy patients with frequent nocturnal seizures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">August 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful System Training</measure>
    <time_frame>72 hours</time_frame>
    <description>Assessment of how well participants learn to use stimulation smart-phone application and headphones, defined as the percentage of subjects with correctly maintained earphones during the first four hours of nocturnal sleep in the first days of use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interictal Discharge frequency</measure>
    <time_frame>72 hours</time_frame>
    <description>IED frequency during nighttime sleep as measured by a 72 hour ambulatory EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>System Adherence</measure>
    <time_frame>2 months</time_frame>
    <description>Percentage of nights during which patients were compliant with the acoustic stimulation device during two months of home use (1 month control acoustic condition, 1 month 1Hz stimulation) determined weekly by patient self-report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>System Use effect on Features of Sleep</measure>
    <time_frame>72 hours</time_frame>
    <description>Effect of system use on sleep features, including time spent in each stage of sleep, delta and spindle power and spatial distribution gather from EEG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Control</measure>
    <time_frame>3 months</time_frame>
    <description>Seizure frequency during control and treatment months gathered from seizure diary and IED frequency gathered from EEG (1 month baseline, 1 month sham stimulation, 1 month 1Hz stimulation).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Acoustic 1Hz Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Background Noise</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Background noise applied via headphones and downloadable phone application during sleep every night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline Seizure Monitoring</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No use of sound system; Patients record seizures in a diary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acoustic 1Hz Stimulation</intervention_name>
    <description>1Hz acoustic pulses delivered during sleep via headphones</description>
    <arm_group_label>Acoustic 1Hz Stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Background Noise</intervention_name>
    <description>Background Noise used as a control</description>
    <arm_group_label>Sham Background Noise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-60 years old&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  MOCA ≥26&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Frequent nocturnal IEDs (≥ 10% of the sleep record)&#xD;
&#xD;
          -  Monitored on the adult epilepsy monitoring unit (EMU, for Aim 1 only) Additional&#xD;
             inclusion criteria for Aim 3&#xD;
&#xD;
          -  Frequent nocturnal seizures (≥1 per week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hearing impairment&#xD;
&#xD;
          -  Diagnosis of a sleep disorder (sleep apnea, periodic limb movements of sleep, or other&#xD;
             medical conditions with frequent arousals)&#xD;
&#xD;
          -  Psychoactive medication use (other than AEDs, for example SSRIs, antipsychotics, BDZ,&#xD;
             or stimulants)&#xD;
&#xD;
          -  Seizures ≤ 24 hours prior to study.&#xD;
&#xD;
          -  Alcohol or recreational drug use in the 24 hours prior to the study&#xD;
&#xD;
          -  BMI ≥ 30&#xD;
&#xD;
          -  MOCA &lt;26&#xD;
&#xD;
          -  History of recent travel across time zones within the 1 month prior to study&#xD;
             activities&#xD;
&#xD;
          -  Shift work for 1 month prior to study activities Additional Exclusion Criteria for Aim&#xD;
             3&#xD;
&#xD;
          -  No medication changes at least 1 month before study, and during 3 months of study&#xD;
             activities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anli Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

